Deep Knowledge Life Sciences and BioViva announce partnership
Seattle-based biotech startup BioViva USA Inc. and London-based biotech investment fund Deep Knowledge Life Sciences (DKLS) are announcing a partnership with the aim of bringing affordable gene therapies to the public.
"BioViva aims to make gene therapy affordable to everyone. Dmitry Kaminskiy, the founding partner of Deep Knowledge Life Sciences, is enthusiastically funding gene therapy, and is himself an early adopter." said BioViva CEO Elizabeth Parrish, adding "We both want to see a world where investors actually live their legacy instead of just leaving it", alluding to a possible future trend.
Parrish made headlines in 2015 when she travelled to an undisclosed location outside the US and personally underwent two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion. It was a gesture intended to prove the safety of the therapies and clear the road ahead for human trials in the US. Months later, BioViva are tracking her results and she has reported no negative side-effects.
"I believed the biotech industry had become over-regulated and that the prevailing model was unlikely to bring new therapies to market in our lifetime. What we needed was a company that would treat diseased patients with no other options and then develop these treatments into preventative medicines. And thus was born BioViva in 2015.", said Parrish.
BioViva's game-changing approach makes it an ideal partner for DKLS with its exclusive focus on disruptive biotechnologies aimed at tackling biomedicine's greatest challenges.
"DKLS rides the crest of a technological wave. We work toward future breakthroughs by selectively funding nascent biotechnologies with practical applications which can be brought rapidly to clinic. This makes DKLS and Bioviva a perfect fit. BioViva led by Liz Parrish has accomplished so much with so little. Now, with DKLS behind them, so much more is possible. The sky's the limit for Bioviva.
We would like to see such partnerships become a new norm. It ought to give fellow investors food for thought: Think hard about what science could achieve tomorrow with intelligent investment", said Dmitry Kaminskiy, the fund's founding partner, who believes that with smarter funding modern science could raise human life expectancy to 120 and beyond.
For Kaminskiy, it's not all about the portfolio. He wants to shift the entire industry up a gear, and put an end to the lack of vision he believes has mired biotechnology for decades: "Millions of human lives are affected by diseases with a genetic component. The sooner we can bring affordable gene therapies and other cell therapies to market, the more needless deaths can be avoided."
About BioViva: BioViva USA, Inc. is a to-clinic gene therapeutics company incorporated in Delaware. BioViva utilizes intramural and extramural peer-reviewed research in order to create marketable therapies for treating age-related diseases and infirmities — including Parkinson's, Alzheimer's, heart-disease, cancer, sarcopenia and kidney failure — at the level of the genome. For more information visit: http://bioviva-science.com
About Deep Knowledge Life Sciences (DKLS): An innovative investment fund which aims to accelerate the development of biotechnologies for healthy longevity. It is London-based subsidiary of Deep Knowledge Ventures. DKLS has gathered eight life science portfolio companies of Deep Knowledge Ventures (DKV), including Insilico Medicine and Pathway Pharmaceutical. For more information visit: http://deepknowledge.life